GEP20146100B - Novel phenylimidazole derivative as pde10a enzyme inhibitor - Google Patents

Novel phenylimidazole derivative as pde10a enzyme inhibitor

Info

Publication number
GEP20146100B
GEP20146100B GEAP201012536A GEAP2010012536A GEP20146100B GE P20146100 B GEP20146100 B GE P20146100B GE AP201012536 A GEAP201012536 A GE AP201012536A GE AP2010012536 A GEAP2010012536 A GE AP2010012536A GE P20146100 B GEP20146100 B GE P20146100B
Authority
GE
Georgia
Prior art keywords
enzyme inhibitor
pde10a enzyme
phenylimidazole derivative
novel phenylimidazole
novel
Prior art date
Application number
GEAP201012536A
Other languages
English (en)
Inventor
Mohamed M Farah
John Paul Kilburn
Jacob Nielsen
Morten Langgård
Jan Kehler
Andreas Ritzen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2009/050134 external-priority patent/WO2009152825A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of GEP20146100B publication Critical patent/GEP20146100B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GEAP201012536A 2009-06-19 2010-06-17 Novel phenylimidazole derivative as pde10a enzyme inhibitor GEP20146100B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050134 WO2009152825A1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors

Publications (1)

Publication Number Publication Date
GEP20146100B true GEP20146100B (en) 2014-05-27

Family

ID=42321053

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201012536A GEP20146100B (en) 2009-06-19 2010-06-17 Novel phenylimidazole derivative as pde10a enzyme inhibitor

Country Status (28)

Country Link
EP (1) EP2443105B1 (enExample)
JP (1) JP5768044B2 (enExample)
AR (1) AR077144A1 (enExample)
AU (1) AU2010262190B2 (enExample)
BR (1) BRPI1015983A2 (enExample)
CA (1) CA2765750A1 (enExample)
CR (1) CR20110654A (enExample)
CY (1) CY1115971T1 (enExample)
DK (1) DK2443105T3 (enExample)
DO (1) DOP2011000397A (enExample)
ES (1) ES2527216T3 (enExample)
GE (1) GEP20146100B (enExample)
GT (1) GT201100322A (enExample)
HR (1) HRP20141222T1 (enExample)
IL (1) IL216684A (enExample)
MA (1) MA33367B1 (enExample)
MX (1) MX2011013400A (enExample)
MY (1) MY156785A (enExample)
NZ (1) NZ597203A (enExample)
PL (1) PL2443105T3 (enExample)
PT (1) PT2443105E (enExample)
SG (1) SG176680A1 (enExample)
SI (1) SI2443105T1 (enExample)
SM (1) SMT201500003B (enExample)
TW (1) TW201100430A (enExample)
UA (1) UA106378C2 (enExample)
WO (1) WO2010145668A1 (enExample)
ZA (1) ZA201109271B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2013034758A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
WO2013034755A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
BR112020013743A2 (pt) * 2018-11-06 2020-12-01 H. Lundbeck A/S hemiadipato de 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina
WO2020094592A1 (en) * 2018-11-06 2020-05-14 H. Lundbeck A/S Compounds for treating negative symptoms and cognitive impairments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2004024705A1 (ja) 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited ５員複素環化合物
AU2003288352A1 (en) 2002-10-30 2004-06-07 Centre National De La Recherche Scientifique (Cnrs) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
EP1641457B1 (en) 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
MXPA05013553A (es) 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1723134A2 (en) 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
BRPI0511854A (pt) 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2578996A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
MX2008010668A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
CA2765750A1 (en) 2010-12-23
ES2527216T3 (es) 2015-01-21
HRP20141222T1 (hr) 2015-02-27
WO2010145668A1 (en) 2010-12-23
AU2010262190A1 (en) 2012-01-19
SG176680A1 (en) 2012-01-30
AR077144A1 (es) 2011-08-03
MY156785A (en) 2016-03-31
CY1115971T1 (el) 2017-01-25
ZA201109271B (en) 2013-02-27
GT201100322A (es) 2014-02-06
IL216684A (en) 2016-03-31
MA33367B1 (fr) 2012-06-01
JP5768044B2 (ja) 2015-08-26
JP2012530086A (ja) 2012-11-29
SI2443105T1 (sl) 2015-02-27
UA106378C2 (ru) 2014-08-26
PL2443105T3 (pl) 2015-03-31
CR20110654A (es) 2012-03-09
EP2443105A1 (en) 2012-04-25
IL216684A0 (en) 2012-02-29
PT2443105E (pt) 2015-01-14
DOP2011000397A (es) 2012-07-15
TW201100430A (en) 2011-01-01
SMT201500003B (it) 2015-03-05
BRPI1015983A2 (pt) 2016-04-19
MX2011013400A (es) 2012-02-21
DK2443105T3 (en) 2015-01-12
EP2443105B1 (en) 2014-10-29
AU2010262190B2 (en) 2013-01-31
HK1171446A1 (en) 2013-03-28
NZ597203A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
NZ597203A (en) Novel phenylimidazole derivative as pde10a enzyme inhibitor
EA201270046A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
SG10201809638YA (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
PL3482767T3 (pl) Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
NZ608376A (en) Pyrazine derivatives as enac blockers
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
NZ600874A (en) Fluorinated derivatives of deferiprone
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
SI2285808T1 (sl) Spiro-indolni derivati za zdravljenje parazitskih bolezni
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
PH12013500401A1 (en) Quinoxaline compound
NZ610853A (en) Phenylketone carboxylate compounds and pharmaceutical uses thereof